Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/11/2025
• Auteurs : Stephen SmithFrancesc Bosch AlbaredaDanielle WallaceJose Villasboas BisnetoCarlos GrandeJean-Pierre MarolleauReid MerrymanLuca ArcainiAntonio PintoNorma GutiérrezBrian TillCristina García HerceMaria Rocio Figueroa MoraPierre MorelSara RattottiPhilippe RinaudoJean-Marie CarpierJan FagerbergPier Luigi ZinzaniPhilippe ArmandJonathan FriedbergStephen Ansell
• Organismes : Fred Hutchinson Cancer Research Center [Seattle] Wilmot Cancer Institute [Rochester] Mayo Clinic [Rochester] Universidad de Navarra [Pamplona] CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 Dana-Farber Cancer Institute [Boston] Fondazione IRCCS Policlinico San Matteo [Pavia] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy] Instituto de Investigación Biomédica de Salamanca Fred Hutchinson Cancer Research Center [Seattle] Service de radiothérapie [CHU Amiens] Fondazione IRCCS Policlinico San Matteo [Pavia] Yale University [New Haven] Fred Hutchinson Cancer Research Center [Seattle] Alma Mater Studiorum Università di Bologna = University of Bologna [Bologne] Dana-Farber Cancer Institute [Boston]
• Publié dans Blood le 28/10/2020

---

Résumé : Background Single-agent R is a common 1st-line therapy for patients (pts) with FL, especially those with low-tumor burden advanced stage disease or comorbidities. EO is a therapeutic vaccine generated from non-self-protein sequences from gut bacteria, including 4 HLA-A2 CD8 T cell epitopes that mimic B cell-specific markers: CD20, CD22, CD37 and BAFF-receptor. EO also contains a CD4 helper epitope UCP2. EO expands pre-existing memory CD8 T cells recognizing non-self-protein sequences from gut bacteria which can cross-react with B cell antigens on tumor cells. The aim adding EO to R is to safely increase the depth and duration of responses. Methods Cohort 3 (C3) of trial EONHL1-20/SIDNEY includes pts with HLA-A2 and previously untreated low-tumor burden (GELF) FL grade 1-3A in need of treatment (per pt/treating physician). Pts receive EO (300μg/peptide) SC with adjuvant Montanide, q2 weeks (w) x 4, then q4w for a total of 12 doses, combined with R starting at w7 (375 mg/m2 IV q1w x4, then q8w x4). For immune responses blood mononuclear cells were assayed by flow cytometry and EO-mimic or B cell peptide specific tetramers without in vitro stimulation. The primary objective is to assess safety; secondary objectives include EO immunogenicity and preliminary efficacy. Results As of July 2025, the 6 planned pts had started EO. Median age was 66 years (range 46-73); 5 ECOG 0/1 ECOG 1; 1 Ann Arbor stage III/5 stage IV; FLIPI low risk 2/intermediate 2/high 2; FLIPI-2 low risk 2/intermediate 4. At median follow-up 10.6 months (mo) 4 pts completed and 2 are ongoing on EO. Median treatment duration was 43 w (range 2-43). Best response by Lugano in the 6 pts included 4 complete (CR) and 2 partial responses (PR). Median time to PR/CR was 17.1 w (range 6.0-18.0). Currently there is only 1 (not yet confirmed) progression at 20.5 mo. All 5 immune response evaluable pts had expansion of CD8 T cells specific for EO mimic and B cell target peptides during treatment; 4 of 5 had detectable expansions at w5 (1st testing time). Currently, the longest tested immune response is at w65 and positive for both EO mimic and B cell target peptides. Expanded specific CD8 T cells had a memory phenotype predominantly composed of effector memory (TEM) cells but also including central memory (TCM) and terminally differentiated effector memory CD8 T (TEMRA) cells. Across the 5 pts, the medians of max % (sum of specific CD8 T cells targeting either the 4 EO mimic peptides or the 4 B cell antigen epitopes at a specific timepoint) among all peripheral CD8 T cells were 0.71% (range 0.19-3.97) for EO mimic and 0.33% (0.20-1.30) for B cell target peptides. The most common EO-related adverse events (AEs) were local administration site reactions (erythema, pain, induration). These included Gr (Grade) 1 reactions in 3 pts, Gr 2 in 1 pt, and Gr 3 in 1 pt; latter being ulceration with EO-interruption at w10.1, and in context of a strong immune response against EO mimic [3.97% of all peripheral CD8 T cells at w5] and B cell target [1.30%] peptides, and CR from w16.7. Other EO related AEs were Gr 1 lymph node pain (1 pt), and related to both EO and R were Gr 2 urticaria (1 pt) and Gr 1 fatigue (1 pt). Only R related were Gr 2 infusion related reaction (3 pts), Gr 2 enterocolitis infection (1 pt), and in 1 pt each Gr 1 flushing, anemia, headache and diarrhea. There were no further Gr 3-4 AE and no death on treatment/follow-up. Complete B cell depletion was seen in 5 pts tested at w18 (R added w7); no recovery in the range of w30-65. Only 3 infections were reported, per above enterocolitis, and 2 cases of COVID-19 both resolved without sequalae. ConclusionsThe combination of EO with R has a predictable and manageable safety profile, with EO only adding local administration site reactions to the well-known R safety profile. In this feasibility cohort all evaluable pts developed a specific immune response against EO and B cell targets, and a Lugano objective response. The combination of EO and R is feasible and can be evaluated in further trials. Updated results will be presented at the meeting.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/11/2025
• Auteurs : Arthur BobinJérôme LambertJill CorreSalomon ManierAurore PerrotLionel KarlinMurielle RousselNoémie BigotKamel LaribiClaire DingremontChristophe RoulValentine RichezClara MarietteSophie RigaudeauClaire CalmettesMamoun DibMourad TiabLaure VincentJacques DelaunayJean-Pierre MarolleauPascal GodmerAnaïs SchavgoulidzeLaurent FrenzelRonan Le CallochÉmilie ChalayerHélène GardeneyMagaret MacroBruno RoyerStéphanie HarelOlivier DecauxBertrand ArnulfKarim Belhadj MerzougCyrille TouzeauMohamad MohtyPhilippe MoreauThierry FaconCyrille HulinXavier Leleu
• Organismes : Ischémie reperfusion, métabolisme et inflammation stérile en transplantation [U 1313] Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation | Epidémiologie Clinique, STatistique, pour la Recherche en Santé Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) Centre de Recherches en Cancérologie de Toulouse Université de Lille Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Recherches en Cancérologie de Toulouse Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] CHU Limoges Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) Hopital Saint-Louis [AP-HP] Centre Hospitalier Le Mans (CH Le Mans) Centre Hospitalier de Bigorre [Tarbes] Centre Hospitalier de la Rochelle - Ré Aunis- Hôpital Saint Louis Centre Hospitalier Universitaire de Nice CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier de Versailles André Mignot Université de Versailles Saint-Quentin-en-Yvelines CENTRE HOSPITALIER PÉRIGUEUX Centre Hospitalier Universitaire d'Angers Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Hôpital Saint Eloi [CHU Montpellier] Hôpital privé du Confluent [Nantes] CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 Centre hospitalier Bretagne Atlantique (Morbihan) Service Hématologie - IUCT-Oncopole [CHU Toulouse] Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Centre hospitalier de Cornouaille Quimper Concarneau [Quimper] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Hopital Saint-Louis [AP-HP] Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Hopital Saint-Louis [AP-HP] Groupe Henri Mondor-Albert Chenevier Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Saint-Antoine [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Universitaire de Bordeaux Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
• Publié dans Blood le 28/10/2020

---

Résumé : Introduction: Sustained minimal residual disease (sMRD) negativity has shown a stronger correlation with survival outcomes than MRD negativity at a single time point or at best response. We evaluated MRD negativity between 12 and 24 months in newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients enrolled in the BENEFIT study. Methods: BENEFIT is a multicenter, phase 3 randomized trial comparing isatuximab-lenalidomide-dexamethasone with or without bortezomib (Isa-Rd ± V) in NDMM TI patients. In the Isa-VRd arm, bortezomib (V) was administered weekly for up to 18 months, dexamethasone was permanently discontinued after 12 months, and isatuximab-lenalidomide (Isa-R) was continued until progression. Data are presented in the intention-to-treat (ITT) population. Results: With a median follow-up of 33.4 months (95% CI, 33.0–34.0), 78 patients (29%) discontinued treatment, primarily due to progressive disease. At 24 months, the MRD negativity rate at 10⁻⁵ was significantly higher in the Isa-VRd arm (odds ratio [OR] 2.26; 95% CI, 1.35–3.79; p=0.002). Sustained MRD negativity at 10⁻⁵ was also more frequent in the Isa-VRd arm (OR 2.73; 95% CI, 1.50–4.80; p=0.0007). Similar results were observed for sMRD at the 10⁻⁶ threshold. Importantly, MRD negativity at both 10⁻⁵ and 10⁻⁶ was evaluated in the t(11;14) NDMM TI subgroup. In this subgroup, MRD negativity rates were consistently lower at all time points up to 24 months, consistent with recent observations from the MIDAS study. Due to the small number of patients per group, no subgroup-specific analysis was feasible. Larger cohorts are required to determine whether t(11;14) MM in TI patients achieves delayed or less frequent MRD negativity, potentially reflecting a MGUS-like phenotype. No new safety signals were observed in either treatment arm, including in high-risk multiple myeloma (HRMM) patients. Conclusion: The BENEFIT study continues to support the efficacy of the quadruplet Isa-VRd regimen in NDMM TI patients, notably through improved sustained MRD negativity rates. These data support Isa-VRd as a new standard of care (SOC) for NDMM TI patients aged 65–79 years, including those with HRMM. ClinicalTrials.gov Identifier: NCT04751877

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/11/2025
• Auteurs : Jose Villasboas BisnetoReid MerrymanStephen SmithDanielle WallaceJean-Pierre MarolleauLuca ArcainiCarlos GrandeFrancesc Bosch AlbaredaAntonio PintoNorma GutiérrezBrian TillMaria Rocio Figueroa MoraPierre MorelSara RattottiCristina García HercePhilippe RinaudoJean-Marie CarpierJan FagerbergPier Luigi ZinzaniJonathan FriedbergPhilippe ArmandStephen Ansell
• Organismes : Mayo Clinic [Rochester] Dana-Farber Cancer Institute [Boston] Fred Hutchinson Cancer Research Center [Seattle] Wilmot Cancer Institute [Rochester] CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 Fondazione IRCCS Policlinico San Matteo [Pavia] Universidad de Navarra [Pamplona] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy] Instituto de Investigación Biomédica de Salamanca Fred Hutchinson Cancer Research Center [Seattle] Service de radiothérapie [CHU Amiens] Fondazione IRCCS Policlinico San Matteo [Pavia] Yale University [New Haven] Fred Hutchinson Cancer Research Center [Seattle] Alma Mater Studiorum Università di Bologna = University of Bologna [Bologne] University of Rochester [USA]
• Publié dans Blood le 28/10/2020

---

Résumé : Background Watchful waiting is a common option for pts with asymptomatic FL/MZL. Anti-tumor immunization may delay or even avoid subsequent need for more toxic therapies. EO is designed from non-self-protein sequences derived from gut bacteria, including 4 HLA-A2 CD8 T cell epitopes (synthetic mimic peptides), exhibiting molecular mimicry with specific epitopes on B cell markers (CD20, CD22, CD37, BAFF-receptor). EO also contains a CD4 helper epitope UCP2. EO expands pre-existing memory CD8 T cells recognizing non-self-epitopes from gut bacteria that cross-react with B cell antigens on tumor cells. Methods Cohort 2 (C2; planned accrual 25 pts) of EONHL1-20/SIDNEY includes HLA-A2+ pts with previously untreated FL/MZL not in need of treatment. Pts receive EO (300μg/peptide) SC with adjuvant Montanide, q2 weeks (w) x 4, then q4w, for 12 total doses. For antigen-specific immune responses, peripheral blood mononuclear cells were assayed by flow cytometry using EO-mimic or B cell peptide specific tetramers without in vitro stimulation. IFN-γ ELISPOT was used to evaluate response to UCP2 and anti-CD3. Primary endpoint is objective response rate (ORR) per Lugano 2014. A pre-defined futility boundary was applied (ORR uninteresting=5%/promising=20%). Finding at least 3 of 25 pts with ORR would meet criteria to continue development (chance of 13% and 90% for true ORR of 5% and 20%, respectively). Results As of July 2025, 22 pts had started EO. Median age 59 years (range 32-86); 9 female; 19 ECOG 0/3 ECOG 1; 19 FL/3 extranodal MZL (ENMZL); 3 Ann Arbor stage I-II/8 stage III/11 stage IV; FLIPI low risk 8/intermediate 8/high 6; FLIPI-2 low risk 12/intermediate 7/high 3; 19 GELF neg/3 pos. At a median follow-up for progression of 9.4 months, 9 pts completed EO, 4 stopped for progressive disease (PD), 2 due to PI/pt decision; 7 ongoing. Median treatment duration 38 w (range 4-39). Among 19 evaluable pts, best Lugano response was 3 complete (CR) and 6 partial responses (PR) (ORR 47% [95% CI 24%–71%]; CR-rate 16% [3%-40%]), 6 stable disease (SD), and 4 PD. ORR by PET-CT was 29% (n=14) w6, 39% (n=18) w19, 46% (n=13) w42; corresponding CR rates were 0%, 11%, 15%. Median time to response 17.1 w (range 5.3-41.1). Currently there are only 2 confirmed PD events in pts with prior PR/CR. Among 8 pts with an initial indeterminate response per LyRIC 2016 followed by a confirmatory scan, 4 pts did not have confirmed PD; a possible atypical response pattern rate of 50% on EO (occurring 5.3-41.9 w after start of EO). In 16 immune response evaluable pts, 88% and 81% had expansion of CD8 T cells specific for EO mimic and B cell target peptides, respectively. Expanded specific CD8 T cells had a memory phenotype dominated by effector memory (TEM) and central memory cells. At w5, 7 clinical responders and 7 non-responders were evaluable; more responders had a positive immune response against EO mimic (Chi-square p=0.025) and B cell target (p=0.047) peptides. Max expansion (response sum for 4 EO mimic or 4 B cell target peptides at a single timepoint w3-w8) of specific CD8 T cells (% of all peripheral CD8 T cells) was higher for responders than non-responders both for EO mimic (Mann Whitney p=0.018) and B cell target (p=0.017) peptides. Pts (4) with an initial indeterminate response (LyRIC 2016) had a higher max expansion of B cell target peptide specific CD8 T cells vs 4 pts with a typical progression pattern (Mann Whitney p=0.018) and vs all other 12 pts evaluable for immune response (p=0.029). There was no difference in CD4 T cell response to UCP2 in responders vs non-responders (induction or max immunity w3-w8). Anti-CD3 expansion of T cells indicating T cell intrinsic activation potential did not correlate with clinical response (baseline or max). The most common EO-related adverse events (AEs) were Gr (Grade) 1 (10 pts) and Gr 2 (6 pts) local administration site reactions. Other related AEs in >1 pt were Gr 1 headache (3 pts) and Gr 1-2 fatigue (3 pts). Asthenia lasting 2 days was the only related Gr 3 AE. There were 4 unrelated Gr 3 AEs (gastroenteritis, GI-hemorrhage, inguinal hernia, and syncope). There were no Gr 4-5 AE. ConclusionsEO has a favorable safety profile and is preliminary associated with an ORR of 47%, exceeding the pre-specified boundary for promising activity. The speed and level of expansion of both EO mimic and B cell target peptide specific CD8 memory T cells are associated with objective response. Results will be updated.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Tomaso BeringheliClément JavauxSandrine RouxEvelyne BraunPierre ChauvelotSylvain GoutelleThomas BriotJudith CottinCéline DupieuxJohanna BoulantAnne ConradFlorence AderTristan FerryFlorent ValourTristan FerryTristan FerryFlorent ValourClaire Triffault-FilitAgathe BeckerAnne ConradEvelyne BraunFlorence AderIsabelle EberlJoanna-Isabelle Kurban Bessa LippmanLorena Van-Den-BogaartMarie SimonOlivier BahuaudPierre ChauvelotSandrine RouxSarah SouegesSophie LandreThomas PerpointClément JavauxMarie WanCécile BataillerSébastien LustigElvire ServienGerald DelfosseGuillaume MesnardJean BaltzerJulien ErardNicolas CanceSébastien MartresFranck TrouilletStanislas GunstAlexandre CouraudonAnthony VisteFabien EwaldJean-Luc BesseMatthieu CotteMichel FessyPhilippe ChaudierThomas CuinetVianney DerreveauxAntoine BertaniAntoine ColasFrédéric RongierasJean-Baptiste MassonLéonard VézoleMaxime RarchaertVincent PibarotAram GazarianArnaud WalchChristophe GaillardGaetan VanpoulleLouis DucharneLyliane LyNael Ben-HadidSelma LahlaliThibault DruelVictor RutkaAlain-Ali MojallalAbdulrahman HashimGuillaume HenryHélène PersonMathilde LhermAudrey Chevreau-CilibertiCaroline MacabéoFrédéric AubrunKaissar RouhanaMikhail DziadzkoCéline DupieuxTiphaine Roussel-GaillardLaetitia BeraudMatthieu Curtil-Dit-GalinAni HorikianAnne-Lise MaucotelCamille KolendaJean-Philippe RasigadeAlexis TrecourtDavid GicquelGrégoire VervustIsabelle MorelecJean-Baptiste PialatJoris LavigneNicolas StacoffeAgnes HenryNoémie VieuxRomain GarreauThomas BriotSylvain GoutelleJohanna Boulant
• Organismes : Hôpital de la Croix-Rousse [CHU - HCL] Hôpital de la Croix-Rousse [CHU - HCL] Lyon Bone and Joint Infection Study Group Hospices Civils de Lyon Université Claude Bernard Lyon 1 - Institut des Sciences Pharmaceutiques et Biologiques Hospices Civils de Lyon Evaluation et modélisation des effets thérapeutiques [LBBE] Université Claude Bernard Lyon 1 Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Laboratoire d'automatique, de génie des procédés et de génie pharmaceutique Hospices Civils de Lyon Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Pathogénie des Staphylocoques – Staphylococcal Pathogenesis [CIRI] Centre International de Recherche en Infectiologie Pathogenèse des légionelles- Legionella pathogenesis [CIRI] Hospices Civils de Lyon Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Hospices Civils de Lyon Hospices Civils de Lyon Hospices Civils de Lyon Hospices Civils de Lyon Hospices Civils de Lyon Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL] Centre International de Recherche en Infectiologie Pathogenèse des légionelles- Legionella pathogenesis [CIRI] Lyon Bone and Joint Infection Study Group Centre International de Recherche en Infectiologie Hospices Civils de Lyon Hospices Civils de Lyon Laboratoire de Biomécanique et Mécanique des Chocs Hospices Civils de Lyon Laboratoire de Biomécanique et Mécanique des Chocs Hospices Civils de Lyon Laboratoire de Biomécanique et Mécanique des Chocs Hospices Civils de Lyon Laboratoire de Biomécanique et Mécanique des Chocs
• Publié dans Journal of Antimicrobial Chemotherapy le 31/10/2020

---

Résumé : Abstract Background and objectives Due to its potentially better long-term haematologic tolerance compared to linezolid, tedizolid represents an attractive option for prolonged antibiotic therapy in complicated/chronic Gram-positive infections. However, there is little information regarding the risk of peripheral neurological toxicity, representing another obstacle to the extended use of oxazolidinones. Reporting neurologic adverse events occurring during tedizolid therapy for chronic implant-associated infections. Patients and methods Patients experiencing tedizolid-associated neurologic adverse events were retrospectively described in a case series. Results Five patients (four males; age range, 65–75 years) receiving tedizolid (200 mg q24h) as long-term suppressive therapy for chronic implant-associated infection presented with peripheral neuropathy. In four cases, tedizolid was used after discontinuation of linezolid for toxicity, including one case of neuropathy. Three had at least one additional risk factor for neuropathy (including two diabetes, one of them with diabetes-related nephropathy). Neuropathic symptoms [paraesthesia (n = 2), worsening of pre-existing neuropathy (n = 2), dysesthesias (n = 1)] appeared after a median of 12.4 (IQR, 8.2–13.3) months of tedizolid treatment. Electromyoneurography (EMNG) confirmed axonal sensory polyneuropathy in all but one patient for which EMNG was still within normal ranges, but compatible with incipient neurotoxicity. Tedizolid was stopped in all patients, three patients required specific treatment for neuropathic pain. At last follow-up [2.4 (IQR, 1–2.5) years from tedizolid discontinuation], clinical recovery from neuropathy was noted in three patients. The two patients with persistent neuropathy symptoms were diabetic; one showed EMNG improvement. Conclusions Prolonged used of tedizolid may be associated with peripheral neurologic toxicity, which should be monitored in at-risk patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Gaspard SucJulien DreyfusJulien TernacleThierry Le TourneauPhilippe DemersLinrui GuoAngel Yi Nam FuJean Claude DibMohammad Al FadhalahThays SokolovAmedeo AnselmiDidier TchétchéOphélie Brault MeslinAnge GoutondjiYoan Lavie-BadiePatrick SeknadjiAugustin CoisneDimitri ArangalageAnne BernardUsha ManianMalek KassAntonio FioreArnaud MaudiereYohann BohbotAurélien SeemannNadjib HammoudiLoïc BièrePierre-Yves LerouxJessica ForcilloAntoine JeuMohammed NejjariOlivier HuttinMartine GilardClaire BouletiDavid HarnettJean-Francois LegareThiziri Si MoussiJian YeCatherine SportouchBindu BittiraLaura MunteFabrice BauerHoward Leong-PoiAli Fatehi HassanabadThomas ModineJordan BernickGeorge WellsRoja GaudaBernard IungWilliam KentMichael W.A. ChuDenis BouchardJean-François ObadiaDavid Messika-Zeitoun
• Organismes : University of Ottawa Heart Institute Centre cardiologique du Nord CHU de Bordeaux Pellegrin [Bordeaux] Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] Institut du Thorax [CHU Nantes] Montreal Heart Institute - Institut de Cardiologie de Montréal Western University [Ontario] University of Ottawa Heart Institute Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] Hospices Civils de Lyon Centre Hospitalier Universitaire [Rennes] Laboratoire Traitement du Signal et de l'Image Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Toulouse Hôpital Privé Jacques Cartier [Massy] Centre Hospitalier Régional Universitaire [CHU Lille] Cardiovascular Research Foundation [New York, NY, USA] Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 Institut Pasteur de Lille Laboratoire de Recherche Vasculaire Translationnelle Institut de neurophysiopathologie Hôpital Henri Mondor CHU Marseille Cardiologie [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 CHU Pitié-Salpêtrière [AP-HP] University of Ottawa Heart Institute Montreal Heart Institute - Institut de Cardiologie de Montréal Hospices Civils de Lyon University of Ottawa Heart Institute
• Publié dans Canadian Journal of Cardiology le 01/11/2020

---

Résumé : Background Calcified mitral valve disease (CMVD) is an increasingly recognized condition associated with specific management challenges. MITRACURE, a large multicenter observational registry conducted in France and Canada, provides real-world insights into the characteristics and outcomes of patients with CMVD undergoing MV surgery. Methods Among the 3,522 patients included in MITRACURE, patients identified with CMVD were matched 4:1 for age, sex, and concomitant procedures with patients with myxomatous MV disease. Results Sixty patients (2%) with CMVD were matched to 240 with myxomatous MV disease. Compared to the myxomatous cohort, CMVD patients had a greater burden of cardiovascular risk-factors, more comorbidities, and a more advanced presentation, with 70% vs. 52% in NYHA class III–IV (P=0.01). In-hospital mortality and major complication rates (composite of death, cardiogenic shock/low cardiac output requiring inotropes, acute renal failure requiring dialysis, and stroke or transient ischemic attack) were significantly higher in CMVD than myxomatous patients (20% vs. 4%, and 38% vs. 20%, both P<0.01). Median EuroSCORE II was slightly higher in CMVD patients (3.5 [IQR 2.2-5.7]) compared with those with myxomatous disease (2.6 [IQR 1.5-4.2], P<0.01). However, the observed mortality in the CMVD group was three to four times higher than predicted, whereas in the myxomatous group it was consistent with predicted values. Conclusion CMVD defines a high-risk surgical population with substantial baseline cardiovascular morbidity and markedly elevated postoperative mortality and complication rates that were substantially underestimated by EuroSCORE II emphasizing the need for refined risk prediction models and individualized management strategies in this subset of patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Marianne DebueThibault GuinaldoDavid AyacheFrédéric BachevillerSarah BarbierLéa BerthomierEtienne BlotStephan ConseilPierre DanielWarren DanielEdmée DurandFlorian GibierStéphane GuevelFrank GuibertJean-Baptiste HernandezOlivier JaronArnold ManhavalAdrien MaussGilles MontesquieuCoralline NicolasPhilippe PalanyOlivier PeronIsabelle PfaffenzellerBruno PradelStéphane Saux-PicartAnastasiia TarasenkoBenoît ThoméThéo Tournier
• Organismes : Centre d’Etudes en Météorologie Satellitaire Centre d’Etudes en Météorologie Satellitaire Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Services Météorologiques de Météo-France Direction des Services Météorologiques de Météo-France Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Centre d’Etudes en Météorologie Satellitaire Institut Des Substances et Organismes de la Mer - UR 2160 Centre National d'Études Spatiales [Toulouse] Météo-France Direction des Services Météorologiques de Météo-France
• Publié dans La Météorologie le 02/11/2020

---

Résumé : Depuis 2011, des échouements massifs de sargasses ont lieu dans les Antilles françaises. Afin de limiter les conséquences néfastes engendrées lors de leur décomposition sur les plages, les plans de prévention et de lutte contre les sargasses ont identifié le besoin de mettre en place un dispositif de surveillance et de prévision des échouements en appui des institutions publiques. Cette prévision, développée et opérée à Météo-France depuis 2019, constitue un service public unique en Europe. Elle repose sur trois axes : la détection satellitaire des sargasses, la modélisation de leur dérive et la production de bulletins de risque d'échouement.

---

Fichiers liés : article_final.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Romain StammlerAlexandre ValléeJulien RohmerNathalie GrardelNoémie AbisrorWadih Abou ChahlaFélix AckermannAntoine BaudetNabil BelfekiRaouf Ben AbdelaliAudrey BidetJean-Sébastien BladéSéverine BleuseBernard BonnotteMohammed Azzedine BouderbalaJean-Michel CayuelaSafia ChebrekJérémie DionAntoine DossierNicolas DuployezStanislas FaguerPascale Flandrin-GrestaLionel GalicierCatherine GodonMaximilien GrallVincent JachietMathieu JouvrayMathieu JouvrayIrina LatuEmmanuel LedoultEtienne LenglineAmélie LeursLudovic LhermitteFrançois LifermannNicolas LimalBertrand LiogerMaxime LugosiIrène MachelartMickaël MartinNihal MartisLaurent MauvieuxSara Melboucy-BelkhirCatherine MohrGuillaume MoulisMarie Joelle MozicconacciDina NaguibAntoine NéelFranck NicoliniRoderau OuthKewin PanelClaude PreudhommeMathieu PuyadeThomas QuemeneurViviane Queyrel MoranneJérôme ReyPhilippe RousselotNicolas SchleinitzBorhane SlamaDelphine Staumont-SalléCamille TailléLouis TerriouLudovic TrefondJean François ViallardJean-Emmanuel KahnGuillaume LefèvreMatthieu GrohSébastien AbadHenri Abi RachedAmir AdedjoumaDidier AdikoChristian AgardKais AhmadNuri AhwijJean-Christophe AlloZineb AmraniAchille AoubaHélène AubertNathalie BaizeAndré BaruchelCaroline BealIssam BelhajMaxime BembaAlice BerezneClément BeuvonMarie Beylot BarryOdile Beyne RauryPhilip BielefeldConstance BlandinMario BoisseauCaroline BonmatiCécile BorelDaoud BouredjiHélène BoutrouxAnne BrignierBenoit BrihayeMarc BrouillardThomas BrunetClaude-Eric BulaboisFrance CamposMartin CarrePascal CathébrasEmilie CayssialsEmilie ChalayerCécile ChenivesseJean‐claude ChomelValérie CoiteuxThibaut ComontAdrien ContejeanVincent CottinAmélie Couteau ChardonPriscille CoutureYoann CrabolGwenvael DanicAdrien DanielStéphane DarreSebastien de AlmeidaAdèle de MassonEric DelabesseThomas DelayeFréderic DezoteuxViviane DubruilleClairelyne DupinMylène DuplanCécile Audrey DurelMikaël EbboJaphete Darline Elenga KoengaAberrazak El YamaniAlexandra EspitiaPascaline EtancelinGabriel EtienneNicolas EtienneMarine EustachePhilippe EvonOlivier FainSophie Georgin LavialleBertrand GodeauCécile GoldenTiphaine GoulenokClément GourguechonCarine GreibAurélien GuffroyPhilippe GuilpainEmmanuel GyanÉric HachullaMarion HermetFrançoise HuguetLucas InchiappaIbrahim JdidElisa JolyKatayoun JondeauMorgane JoubertAnne JourdainGalith KalmiBrigitte LagrangeJudith Landman-ParkerMathilde Le BrunNoémie Le GouellecCaroline LejeuneSarah Le NaourMathilde LeclercqPaul LegendreClaire Le PenduFaustine LhommeOlivier LidoveElena LopinetPierre LozachAurélie MadelonLéa MairotFréderic MaloiselAnne MarfaingVictor MargelidonIbrahim MarrounAgathe MasseauFrançois MaurierArsène MekinianMathieu MeunierMarc MichelChafika Morati-HafsaouiMarjolaine MorgandEmilie MullerThierry MuronAlexandre NguyenHubert NiellyMario OjedaThomas PapoRomain PauleArnaud PetitJean Michel PignonCamille Prot-LeurentJérome RazanamaherySabine RevuzSophie RigaudeauEtienne RiviereCédric RossiManon RoucoulesJean-Philippe RougierMathilde RoumierBenedicte RouvièreFrédéric Roy PeaudArnaud Saint LezerLaurent SaillerGaetan SauvetreLéa SaveyQuentin ScanvionLaurent SchwarbDamien SèneLaurence SimonBohrane SlamaMicha SrourFelipe SuarezBenjamin SubranSuzanne TavitianColas TcherakianNathalie TieulieJose Miguel TorregrosaElise ToussaintJulie TrichereauRémi VatanGael VaudourAlexandre VlakosSorin VisanicaLaurent VoilatFanny VuottoStéphanie WaninHacène ZerazhiJean Marc ZiniStéphane Zographos
• Organismes : Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Hôpital Foch [Suresnes] Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Sorbonne Université Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre Hospitalier d'Annecy Genevois Groupe Hospitalier Sud Ile-de-France Laboratoire CERBA [Saint Ouen l'Aumône] CHU de Bordeaux Pellegrin [Bordeaux] Hopital d'instruction des armées Sainte-Anne [Toulon] Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Service Hématologie - IUCT-Oncopole [CHU Toulouse] Service Médecine interne et immunopathologie clinique [CHU Toulouse] Département de Néphrologie et Transplantation d'organes [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Service Médecine interne [CHU Toulouse] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Centre Hospitalier Régional Universitaire [CHU Lille] Institute for Translational Research in Inflammation - U 1286 Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Infection et inflammation Centre de Recherches en Cancérologie de Toulouse Laboratoire Hématologie - IFB [CHU Toulouse] Laboratoire Hématologie - Rangueil [CHU Toulouse] Service Hématologie - IUCT-Oncopole [CHU Toulouse]
• Publié dans Journal of Allergy and Clinical Immunology: In Practice le 27/10/2020

---

Résumé : The FIP1L1-PDFGRA (F/P)-associated hypereosinophilic syndrome (HES) is a rare condition. The F/P fusion gene testing is one of the first-line investigations in patients with unexplained eosinophilia and yields poor diagnostic performance. OBJECTIVE: To build and validate the factor interacting with PAPOLA and CPSF1 (FIP) score: a set of weighted criteria warranting testing for the F/P fusion gene. METHODS: We merged data from 151 patients with F/Passociated HES and 320 patients with either F/P-negative HES (n = 279) or hypereosinophilia of undetermined significance (n = 41). Training and validation cohorts (comprising, respectively, 90% and 10% of all patients) were randomly dichotomized. Variables with a P value less than .20 in univariate analysis were included in the multivariable forward-backward logistic regression model to assess their independent contribution to testing positive for the F/P fusion gene. Beta coefficients from multivariable logistic regression were used to assign points for the construction of the score. RESULTS: Age younger than 66 years, male sex, splenomegaly, lymphomatoid papulosis, absence of gastrointestinal involvement, high serum vitamin B 12 , high serum tryptase, and normal serum immunoglobulin E levels were the 8 variables retained in the model. The best cutoff value was greater than 48. The model yielded a sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve, respectively, of 88.3%, 93.7%, 87.1%, 94.4%, and 0.962 in the training dataset and of 85.7%, 97.0%, 85.7%, and 97.0%, 0.986 in the validation dataset. CONCLUSIONS: The FIP score highlights the need for closely selecting patients with hypereosinophilia for whom F/P fusion gene testing should be performed, resulting in medical time reduction and substantial cost-savings.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Jérôme RoncalliFrançois RoubilleYves CottinLionel LerouxAnthony MathurJohn IrvingSohail Q KhanNicolas MeneveauDidier BressonThomas HovasseGiulio PompilioAnthony MattaPhilippe HenonGuillaume TrebuchetMatthieu de KalbermattenIbon GaritaonandiaEric SalouxAlain ManriqueNicolas MeyerPierre-Yves MarieDeepak BhattScott D SolomonGilles MontalescotDavid E NewbyFaiez Zannad
• Organismes : Service Cardiologie [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Module Biothérapies CHU Montpellier = Montpellier University Hospital Service de Cardiologie [CHU de Dijon] Département de cardiologie Barts Heart Centre [London, UK] Barts Health NHS Trust [London, UK] Ninewells Hospital and Medical School [Dundee] Queen Elizabeth Hospital University Hospitals Birmingham [Birmingham, Royaume-Uni] NHS Foundation Trust [London] Hôpital Jean Minjoz [Besançon] Centre Hospitalier Emile Muller [Mulhouse] Institut Cardiovasculaire Paris Sud Centro Cardiologico Monzino [Milano] Università degli Studi di Milano = University of Milan Service Cardiologie [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Module Biothérapies CellProthera CellProthera CellProthera CellProthera Service de cardiologie et de pathologie vasculaire [CHU Caen] Service de médecine nucléaire [CHU Caen] Groupe Méthodes en Recherche Clinique [Strasbourg] Défaillance Cardiovasculaire Aiguë et Chronique Service de Médecine Nucléaire [CHRU Nancy] Nancyclotep- Experimental Imaging Platform = Plate-forme d'imagerie moléculaire Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai [New York] Brigham and Women's Hospital [Boston] Harvard Medical School [Boston] CHU Pitié-Salpêtrière [AP-HP] Groupe Action British Heart Foundation Centre of Research Excellence The University of Edinburgh Défaillance Cardiovasculaire Aiguë et Chronique Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris]
• Publié dans JACC: Heart Failure le 29/10/2020

---

Fichiers liés : 1-s2.0-S2213177925005542-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Pierre-André LafonLaurent PrézeauJean-Philippe PinPhilippe Rondard
• Organismes : Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle
• Publié dans Trends in Pharmacological Sciences le 25/10/2020

---

Résumé : Camelid-derived nanobodies offer a promising alternative to conventional antibodies for the treatment of brain disorders. Their current development in models of schizophrenia or Alzheimer's disease highlights their strong therapeutic potential. Optimizing their delivery and ensuring their safety are major challenges, but their modularity and low immunogenicity make them promising candidates for neurotherapy.

---

Fichiers liés : Lafon et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Philippe RyvlinMargaux HuotLuc ValtonLouis MaillardFabrice BartolomeiPhilippe DerambureEdouard HirschVéronique MichelFrancine ChassouxJérôme PetitArielle CrespelArnaud BirabenVincent NavarroPhilippe KahaneBertrand de ToffolPierre ThomasSarah RosenbergAdriano BerniniAnne-Laure CharloisLaura CraciunFatima ChorfaPauline DucouretAxel FerreiraMathilde LeclercqManon MartyBlanca Mercedes AlvarezMilena SampaioAntoine SpahrNoémie Timestit-KurlandMaylis TouyaPascal RoySylvain RheimsC AdamN Andre-ObadiaS AubertFabrice BartolomeiJ BiberonA BirabenFb BoniniSébastien BoulogneV BourgH CatenoixF ChassouxA CrespelJc CurotMd DamianoM de MontaudouinB de ToffolM DenuelleP DerambureSamuel DupontV EidV FrazziniP GelisseE HirschJ IsnardAs JobJ JungP KahaneSl LagardeE LandreP LatourL MaillardC MarchalA Mc GonigalV MichelL MinottiA MontavontV NavarroVh Nguyen-MichelA NicaJ PetitFp PizzoSylvain RheimsSr RosenbergFr RulquinP RyvlinCs SabourdyM SampaioW SzurhajP ThomasD TourniaireAt TrébuchonL TyvaertMp ValentiL ValtonL VercueilJp Vignal
• Organismes : Institut des Epilepsies de l'Enfant et de l'Adolescent Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Centre de recherche cerveau et cognition Centre Hospitalier Universitaire de Toulouse Ingénierie Moléculaire, Cellulaire et Physiopathologie Service de neurologie [CHRU Nancy] Institut de Neurosciences des Systèmes Service d'Epileptologie et de Rythmologie Cérébrale [Hôpital de la Timone, AP-HM] Service de neurophysiologie clinique Pharmacologie de la mort neuronale et de la plasticité cérébrale Centre de référence des épilepsies rares [CHU Strasbourg] Service de Neurologie [Strasbourg] Service de neurologie [Bordeaux] Service de neurochirurgie [AP-HP Hôpital Lariboisière] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Centre Médical de la Teppe Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Institut National de la Santé et de la Recherche Médicale Centre Hospitalier Universitaire [Rennes] Laboratoire Traitement du Signal et de l'Image CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute [GIN] Grenoble Institut des Neurosciences CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Régional Universitaire de Tours Inserm U930 Imagerie et Cerveau Service de Neurologie [CHU Nice] Service Neurologie [CHU Clermont-Ferrand] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Hospital General Universitario "Gregorio Marañón" [Madrid] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
• Publié dans The Lancet Neurology le 27/10/2020

---

Fichiers liés : 1-s2.0-S1474442225003795-main.pdf

---

Source